Business Context and Reporting Period
This Form 6-K filing by Summit Therapeutics PLC (the "Company") is dated May 15, 2018. The report discloses the acquisition of Discuva Limited ("Discuva"), a private company organized under the laws of England and Wales, which was completed on December 23, 2017. The filing provides audited financial statements for Discuva for the period from April 1, 2017, to December 23, 2017, and Unaudited Pro Forma Condensed Combined Financial Information for the fiscal year ended January 31, 2018.
Key Financial Metrics
The filing details the consideration paid for the acquisition of Discuva but does not provide specific revenue, profit, cash flow, or margin figures for the combined entity or Discuva within the text of this summary. The acquisition consideration consisted of:
- Cash Component: £5.0 million upfront, adjusted by Discuva's cash and cash equivalents minus indebtedness, non-ordinary course liabilities, and escrow funds.
- Equity Component: £5.0 million in value, satisfied by the issuance of 2,934,272 ordinary shares at a price of £1.704 per share.
Specific values for debt, liquidity, and operating margins for the reporting periods are not explicitly stated in the provided text; they are contained within the referenced exhibits (Exhibit 99.1 and 99.2).
Material Changes
The primary material change is the consolidation of Discuva into Summit Therapeutics PLC. The Unaudited Pro Forma Condensed Combined Financial Information presents the financial position as if the acquisition had occurred on February 1, 2017. Management notes that actual consolidated results following the acquisition may differ significantly from the pro forma information due to differences between assumptions and actual amounts.
Guidance, Outlook, and Risks
The filing explicitly states that the Pro Forma Condensed Combined Financial Information is for illustrative purposes only and does not purport to project future financial condition or results of operations. No specific forward-looking guidance or management commentary regarding future revenue or profitability is included in the text of this filing. The document notes that the pro forma adjustments are preliminary.
Investor Verification Checklist
- Verify the exact cash consideration paid by reviewing the final closing adjustments in Exhibit 99.1 (Audited Financial Statements of Discuva).
- Review Exhibit 99.2 to analyze the specific pro forma revenue and expense impacts of the acquisition.
- Confirm the dilution impact of the 2,934,272 new shares issued to Discuva shareholders.
- Examine the referenced Annual Report on Form 20-F (filed April 13, 2018) for a detailed description of the transaction.